School of Pharmacy, Zhejiang Chinese Medical University, No. 548 Binwen Road, Hangzhou, Zhejiang, 310053, China.
Cell Death Dis. 2024 May 14;15(5):336. doi: 10.1038/s41419-024-06702-w.
Fibrosis is a reparative and progressive process characterized by abnormal extracellular matrix deposition, contributing to organ dysfunction in chronic diseases. The tumor suppressor p53 (p53), known for its regulatory roles in cell proliferation, apoptosis, aging, and metabolism across diverse tissues, appears to play a pivotal role in aggravating biological processes such as epithelial-mesenchymal transition (EMT), cell apoptosis, and cell senescence. These processes are closely intertwined with the pathogenesis of fibrotic disease. In this review, we briefly introduce the background and specific mechanism of p53, investigate the pathogenesis of fibrosis, and further discuss p53's relationship and role in fibrosis affecting the kidney, liver, lung, and heart. In summary, targeting p53 represents a promising and innovative therapeutic approach for the prevention and treatment of organ fibrosis.
纤维化是一种以异常细胞外基质沉积为特征的修复和进行性过程，导致慢性疾病中的器官功能障碍。肿瘤抑制因子 p53（p53）在不同组织中的细胞增殖、凋亡、衰老和代谢中发挥调节作用，似乎在加剧生物学过程中发挥关键作用，如上皮-间充质转化（EMT）、细胞凋亡和细胞衰老。这些过程与纤维化疾病的发病机制密切相关。在这篇综述中，我们简要介绍了 p53 的背景和具体机制，研究了纤维化的发病机制，并进一步讨论了 p53 在影响肾脏、肝脏、肺和心脏的纤维化中的关系和作用。总之，针对 p53 代表了一种有前途和创新的治疗方法，可用于预防和治疗器官纤维化。
